Table 2.

Patient 1 Drug Metabolism

Gene	Genotype	Phenotype summary	References
CYP1A2 Cytochrome P450 Family 1 Subfamily A Member 2	*1A/*1F	Rapid metabolites may cause toxicity or side effects	RightMed Comprehensive test (OneOme)
CYP2B6 Cytochrome P450 Family 2 Subfamily B Member 6	*1/*6	Decreased activity, active drugs converted to inactive metabolites may cause side effects or toxicity	RightMed Comprehensive test (OneOme)
CYP2C19 Cytochrome P450 Family 2 Subfamily C Member 19	*1/*2	Decreased activity, active drugs converted to inactive metabolites may cause side effects or toxicity	RightMed Comprehensive test (OneOme)
CYP2C Cluster	rs12777823 GA	Altered warfarin clearance	RightMed Comprehensive test (OneOme)
CYP2D6 Cytochrome P450 Family 2 Subfamily D Member 6	*1/*4	Decreased activity, active drugs converted to inactive metabolites may cause side effects or toxicity	RightMed Comprehensive test (OneOme)
COMT Catechol‐O‐Methyltransferase	rs4680 AA	Low activity in the catabolism of neurotransmitters dopamine, epinephrine, and norepinephrine	RightMed Comprehensive test (OneOme), NCBI Gene (www.ncbi.nlm.nih.gov/gene)
F2 Coagulation factor II, thrombin	rs1799963 GA	Increased risk of thrombosis associated with prothrombin thrombophilia	RightMed Comprehensive test (OneOme)
NUDT15 Nudix Hydrolase 15	rs116855232	Increased risk of leukopenia with thiopurine administration	RightMed Comprehensive test (OneOme)
SLC6A4 Solute Carrier Family 6 Member 4	S/S (Sa/Sa)	Reduced expression of serotonin transporter localized in presynaptic neuronal membranes.	RightMed Comprehensive test (OneOme), OMIM (www.omim.org/entry/182138)
UGT1A1 UDP Glucuronosyltransferase Family 1 Member A1	*1/*28	Decreased enzyme activity, increased risk for severe neutropenia with irinotecan and toxicity with nilotinib	RightMed Comprehensive test (OneOme)

Gene/Phenotype summary of variants reported by the RightMed Comprehensive test (OneOme).